Medical Industry News Archive

Click here to search our archive

Print using browser

URGENT MEDICINE RECALL: SANDOZ CEFPODOXIME 40mg/5ml Reg No A39/20.1.1/0397 (50ml and 100ml pack sizes)
Sandoz SA (Pty) Ltd in collaboration with the Medicines Control Council are initiating a Class 2, Type B recall on all batches of Sandoz Cefpodoxime 40mg /5ml (50ml and 100ml pack sizes).

Sandoz Cefpodoxime 40mg/5ml powder for oral suspension is an antibiotic used for short- term treatment of lower and upper respiratory tract infections in infants, children and adults.

The product is being recalled due to lower than expected efficacy, high unknown impurities, discolouration and formation of brownish agglomerates on certain batches of Sandoz Cefpodoxime 40mg/5ml tested during stability monitoring.

Use of the product may lead to weakened patient therapy through insufficient anti-infective treatment resulting in: a patient being contagious to others for a longer time, the development and spread of resistant bacterial strains, and significant therapeutic difficulties in eradication of respective bacteria.

In the interest of patient safety, Sandoz SA (Pty) Ltd request that you immediately return all batches of Sandoz Cefpodoxime 40mg/5ml stock without delay to your supplying wholesaler or distributor for full credit.
Sandoz SA (Pty) Ltd would like to thank you for your co-operation and apologise for any inconvenience caused.

Should you have any enquiries in this regard kindly contact the Sandoz Customer Call Centre 0861 SANCAL or 0861 726 225 during office hours and a technical support 24 hour call no 0768114744.

For full prescribing information please refer to package insert approved by Medical Regulatory Authority

Sandoz SA (Pty) Ltd PO Box 154, Isando 1600 Kempton Park, Gauteng South Africa Tel Fax +27 (0) 11 394 3084    Reg No: 1990/001979/07
Directors: R-A Bassoul (Canadian) J-C Dubos (French) M.M Paleja (Singaporean)  
A Novartis Company

You need to be logged in to see more details. Register Now!

Click here for more information .....
Contact: Carla Urbani-Smith, (Responsible Pharmacist)
Telephone: +27 (0) 11 929 9000
Date: Tuesday, February 14, 2012

Archive News Headlines
Pfizer discontinue Estring Vaginal Ring (estradiol hemihydrate)
Sun Pharma - Out of Stock - Zofer 4 mg 10's (ondansetron)
Adcock Ingram - Change in Marketing Notification - Aclasta (Zoledronic Acid)
Equity Pharmaceuticals launch Garsun 60 mg powder and solvent for solution for injection (artesunate)
Aspen - Out of Stock - Nootropil 400 mg Capsules (piracetam)
Aspen - Out of Stock - Puresis tablets (furosemide)
Cipla - Out of Stock - Mefliam Tablets (Mefloquine 250 mg)
Pharma Dynamics launch Texamer tablets (levocetirizine dihydrochloride)
Cipla - How to use the Sereflo Synchrobreathe inhaler (fluticasone propionate and salmeterol xinafoate)
OPUS Pharmaceuticals - Back in Stock - Kantrexil 20's and 100's Tablets (kanamycin, aminopentamide)
Sandoz - Out of stock - Ranihexal 150 mg tablets 10's and 30's (ranitidine)
Sandoz - Out of stock - Sandoz Cefuroxime 250mg / 500mg
Boehringer Ingelheim discontinue Inflanaze 50 Aqueous Nasal Spray (budesonide)
Adcock Ingram - Back in stock - Adco-Simvastatin 10 mg and 20 mg Tablets
Adcock Ingram - Stock Notification - Estalis 50/140 (oestradiol, norethisterone)
Litha Pharma - Out of Stock - Pur-Bloka 10 mg tablets (propranolol hydrochloride)
Boehringer Ingelheim discontinue Inflammide 200 & 400 Novolizer Powder for inhalation (budesonide)
Boehringer Ingelheim - Out of stock - Co-Pritor 80/12.5 mg tablets (telmisartan, hydrochlorothiazide)
Litha Pharma launch Oratane 40 mg Capsules (isotretinoin)
Sanofi - Out of Stock - Tri-Plen Tablets (ramipril, felodipine)